In8Bio Announces Pricing Of Financing Totaling Up To $46.9 Million In Private Placement
PUBLIC · INABDec 11, 2023
Round Type
Post-IPO Equity
New YorkBiotechnologyTherapeutics
Description
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a securities purchase agreement with certain healthcare-focused institutional investors to raise up to $46.9 million at increasing valuations that includes initial gross proceeds of $14.4 million, extending the Company’s runway into 2025.
Who to call at IN8bio, and when
A new round usually means IN8bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day IN8bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at IN8bio, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
IN8bio
Location
New York, New York, United States
About
IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biology, genetic engineering, and specialized manufacturing to design novel therapies that precisely identify and eradicate tumor cells.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment IN8bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyTherapeutics